



Diagnostica Stago S.A.S.
3, allée Thérèse
92600 Asnières-sur-Seine Cedex • France

+33 (0)1 46 88 20 20
+33 (0)1 47 91 08 91
stago@stago.fr
www.stago.com

Asnières, February 20th 2026

Attn: Head of Laboratory.

Reference : RC-25-0034

FIELD SAFETY NOTICE

Use of STHEMO ANTI Xa M (REF. 01235) on STHEMO 201 and 301

Dear customer,

According to our traceability records, you are a user of our reagent STHEMO ANTI Xa M on a STHEMO instrument.

You are therefore concerned by this Field Safety Notice related to the use of STHEMO ANTI Xa M reagent on these systems.

✓ **Concerned products:**

Device	Code	DI
STHEMO ANTI-Xa M	01235	03607450012354
STHEMO 201	59018	03607450590326
STHEMO 301	59032	03607450590180

✓ **Description :**

Following customer feedback reporting a drift in Anti-Xa Quality Controls results, Stago has identified a progressive contamination of STHEMO Anti Xa M assay by STHEMO PT M reagent on STHEMO automated systems. This contamination leads to an overestimation of the anti Xa results.

According to our investigations, the contamination is linked to a defective rinsing of a raw material contained in the sthemO PT M reagent. The contamination appears progressively and in a more or less pronounced way depending on the number of tests performed using STHEMO PT M compared to the number of tests performed using STHEMO Anti Xa M.



Diagnostica Stago S.A.S.
3, allée Thérèse
92600 Asnières-sur-Seine Cedex • France

+33 (0)1 46 88 20 20
+33 (0)1 47 91 08 91
stago@stago.fr
www.stago.com

Indeed, according to our internal tests, the overestimation of Anti Xa levels becomes noticeable (based on precision of measure) from 250 PT tests performed for 50 Anti Xa tests in a mixed protocol of 5 STHEMO PT M tests for 1 STHEMO ANTI XA M test. It can reach +0.08 IU/mL for a plasma sample at 0.25 IU/mL after 500 PT tests performed for 100 Anti-Xa tests in a single day.

Most of our customers do not perform such high numbers of PT and Anti Xa tests. They consequently do not observe this contamination on their reported Anti Xa results.

Under these conditions, the main identified risk is that a normal plasma sample (without heparin) could be reported with a heparin level > 0.10 IU/mL (the test's limit of detection). Indeed, during our internal tests, the highest value obtained for a normal plasma sample after 500 PT tests performed for 100 Anti-Xa tests was 0.11 IU/mL.

According to our risk analysis, in the worst case scenario, this could lead to a delay in surgery for the patient. However, no adverse incident related to this issue has been reported to us to date.

✓ **Actions :**

You may continue to use sthemO Anti Xa M reagent while monitoring the Quality controls results and, if so, performing an additional daily preventive maintenance.

A new software version will be available soon and installed by your Stago representative. It includes an additional rinsing of the Reagent needle every 20 Anti-Xa tests.

According to our risk analysis, considering the context in which the issue occurred and its detectability through daily quality control monitoring, it does not appear necessary to review previously reported patient results.

We kindly ask you to return the attached acknowledgement form, duly completed and signed, by fax or email, confirming that you have taken note of this letter.

The Competent Administrative Authority of the country of origin (France) has been informed.

Your Competent Administrative Authority has also been informed regarding this issue.

For additional information, please contact your Stago affiliate.

Please accept our apologies for this inconvenience. We thank you in advance for your support.

Yours sincerely,